Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR

NCT07294495 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

HCM - Hypertrophic Cardiomyopathy

Interventions

DRUG: Henagliflozin (SGLT2 Inhibitor)
DRUG: Placebo

Sponsor

Shanghai East Hospital